Leerink Partners Maintains Guardant Health(GH.US) With Buy Rating, Announces Target Price $65
J.P. Morgan Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $60
A Quick Look at Today's Ratings for Guardant Health(GH.US), With a Forecast Between $50 to $70
Morgan Stanley Raises Price Target on Guardant Health to $60 From $52, Keeps Overweight Rating
Research Alert: CFRA Reiterates Buy View On Shares Of Guardant Health, Inc
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), Humana (HUM) and Evolus (EOLS)
